Saturday, 25 May 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 25 May 2024
Listen to this story 
News

Vertex scores world-first approval

Posted 20 November 2023 AM

Vertex has won the first-ever regulatory approval of a therapy based on the CRISPR gene-editing technology, with the UK's MHRA giving it the tick for two indications, sickle cell disease and transfusion-dependent beta-thalassaemia.

The treatment, previously known as exa-cel (exagamglogene autotemcel) and now branded Casgevy, may well make its way to Australia "over time" an Australian spokesperson for Vertex told Pharma in Focus

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (6)

Other (32)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.